TIAA CREF Investment Management LLC grew its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 0.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 111,019 shares of the biopharmaceutical company’s stock after acquiring an additional 785 shares during the period. TIAA CREF Investment Management LLC owned about 0.38% of Ocular Therapeutix worth $1,029,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. American International Group Inc. raised its stake in Ocular Therapeutix by 8.2% during the first quarter. American International Group Inc. now owns 11,138 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 844 shares during the last quarter. Highbridge Capital Management LLC bought a new position in Ocular Therapeutix during the first quarter worth $107,000. State of Wisconsin Investment Board bought a new position in Ocular Therapeutix during the second quarter worth $167,000. Alps Advisors Inc. raised its stake in Ocular Therapeutix by 5.9% during the second quarter. Alps Advisors Inc. now owns 26,201 shares of the biopharmaceutical company’s stock worth $243,000 after buying an additional 1,462 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in Ocular Therapeutix by 22.1% during the second quarter. Rhumbline Advisers now owns 27,386 shares of the biopharmaceutical company’s stock worth $254,000 after buying an additional 4,958 shares during the last quarter. 53.11% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “TIAA CREF Investment Management LLC Has $1.03 Million Stake in Ocular Therapeutix, Inc. (OCUL)” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/11/11/tiaa-cref-investment-management-llc-has-1-03-million-stake-in-ocular-therapeutix-inc-ocul.html.

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) opened at $5.37 on Friday. The company has a quick ratio of 5.20, a current ratio of 4.79 and a debt-to-equity ratio of 0.39. Ocular Therapeutix, Inc. has a twelve month low of $4.70 and a twelve month high of $11.91.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.54) EPS for the quarter, hitting analysts’ consensus estimates of ($0.54). The business had revenue of $523.00 million during the quarter, compared to analysts’ expectations of $0.52 million. Ocular Therapeutix had a negative net margin of 3,241.19% and a negative return on equity of 126.31%. The business’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period last year, the company posted ($0.39) earnings per share. research analysts forecast that Ocular Therapeutix, Inc. will post -2.35 EPS for the current fiscal year.

A number of equities analysts recently weighed in on OCUL shares. Morgan Stanley reissued an “equal weight” rating and set a $8.00 target price (down previously from $16.00) on shares of Ocular Therapeutix in a research note on Friday, July 14th. BTIG Research reissued a “neutral” rating on shares of Ocular Therapeutix in a research note on Monday, July 17th. ValuEngine raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. HC Wainwright started coverage on shares of Ocular Therapeutix in a research note on Wednesday, July 26th. They set a “buy” rating and a $10.00 target price for the company. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $21.00 target price on shares of Ocular Therapeutix in a research note on Monday, September 25th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $22.29.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.

Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix, Inc. (NASDAQ:OCUL).

Institutional Ownership by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Stock Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related stocks with our FREE daily email newsletter.